The 5th World Congress of Cutaneous Lymphomas will take place on April 11-13, 2024, in California, USA at the Pasadena Convention Center. This Congress will highlight high-impact contributions to the management and investigation of cutaneous lymphomas. The Scientific Committee invites you to submit your abstracts in this field for oral and poster consideration. Abstract acceptance will be driven by scientific merit, where only the best submissions will be selected. 

The Committee encourages experts in this field to submit their scientific work and contribute to making this the best meeting yet!


  • Classification/Epidemiology/Prognostic Factors
  • Cutaneous Lymphoma International Consortium – PROCLIPI Studies
  • Biologic Insights
  • Pathogenesis/Biomarkers
  • Tumor Microenvironment
  • Therapeutics/Preclinical Studies
  • Quality of Life/Patient-Reported Outcomes 
  • Challenging Cases of Cutaneous Lymphomas
  • Leading-Edge Research and Future Directions of Cutaneous Lymphomas 
  • Trials in Progress 


As you prepare for your abstract submission, please make sure to review the Abstract Reference Guidelines below and make note of the following details:

  • Abstracts may ONLY be submitted online.
  • There are no restrictions on the number of abstracts you may submit.
  • Science only
    • Abstracts may NOT be about products or lines of business.
  • 500 word limit for body of Abstract
  • No additional submission extensions will be granted.


As you prepare for your abstract submission, please make note of the following eligibility criteria:

  • The Congress will not accept abstract submissions from authors and/or co-authors who are employees of pharmaceutical, biotechnology, or medical technology companies.
  • Authors of all accepted abstracts (oral or poster) are expected to present at the Congress, and therefore, must pay the registration fee to attend. 


All abstracts are subject to an anonymized peer-review by members of the 5th World Congress of Cutaneous Lymphomas Scientific Committee. 

All reviewers, session planners and invited faculty will be required to disclose all financial relationships, helping to ensure high-quality, unbiased presentations and compliance with CME regulations. In addition, First Authors must disclose all financial relationships during the submission process before their abstract will be considered and graded.

Priority for oral presentations will be given to papers not previously presented in international conferences or published in the literature.



December 15, 2023

Extended Submission Deadline

Late-January 2024

Acceptance Notifications via email

February 9, 2024

Withdrawal Deadline

February 29, 2024

Extended Early Bird Registration Deadline

Late-February 2024

Abstracts Added to Online Schedule

April 11-13, 2024

Presentation at the 5th World Congress of Cutaneous Lymphomas


As you prepare for your abstract submission, please make note of the following requirements and instructions.

Word Limit: There is a limit of 500 words for abstract body submission. 

Title: The title should be entered in mixed case (upper and lower-case letters). DO NOT enter the title in all capital or all lower-case letters. Abbreviations may not be used in the title, unless it follows the full name.

Abstract Body:

Include the following:


INTRODUCTION: The introduction should be 2 or 3 brief sentences describing the objectives of the study.

METHODS: A description of the methods used to conduct the study must be included (i.e., retrospective chart review, prospective trial). Detailed descriptions of laboratory techniques should not be included. Do not mention the institution where the work was performed in the body or title of the abstract.

RESULTS: The results should occupy one-half to two-thirds of the abstract, and specific data necessary to evaluate the abstract should be included. If there is concern that additional data would enhance the abstract, then please strongly consider including it. Statements such as "data will be discussed at the presentation" are grounds for disqualification.

CONCLUSION: The conclusion should be no more than 2 or 3 sentences regarding the significance of the results in the context of the original objectives.


INTRODUCTION: The introduction should be 2 or 3 brief sentences describing the case's relevance and importance or what was challenging about it. 

CASE REPORT: A description of the patient's history and details, treatment, patient's progress and outcome. 

DISCUSSION: The discussion should be no more than 2 or 3 sentences that address why decisions were made and what is interesting or noteworthy about the case. Include lessons learned. 



  • All phases of clinical research (Phases I to III, Supportive Care, nonpharmacological Interventions) may be submitted. 
  • Trials must be ongoing, and as a result should not have reached pre-specified endpoints.
    Early results/preliminary data is allowed, rather than noting “Significant Results”, therefore, reporting on “Trial Status” is allowed.

INTRODUCTION: The introduction should be 2 or 3 brief sentences describing the scientific background/rationale for the trial.

METHODS: A description of the methods used to conduct the trial must be included (i.e., Trial design and statistical methods, planned treatment, eligibility criteria, current enrollment). 

TRIAL STATUS: Provide 2 or 3 brief sentences reporting on the trial status
Allowable Information:
Phase I: Phase, Cohorts completed without DLT, Month & Year of when enrollment in current cohort began.
Phase II: How many of the specific number of planned patients have been enrolled, or if prespecified activity goals of the accrual stage were met, Month & Year of when current stage accrual began.
Phase III:  Month & Year the DMC last reviewed the trial, and suggestions that resulted from the review.
Required Information: List the clinical number.

IMPORTANT:  Abstracts with significant data should not be submitted under “Trials in Progress”, but rather be submitted for the other meeting categories providing results or endpoints

CONCLUSION: The conclusion should be no more than 2 or 3 sentences regarding the significance of the trial, highlighting the potential transition of new agents into the clinic. 

Questions to address in the abstract:

1. Why was the study/trial conducted/case reported?

2. How was the study/trial conducted/case reported?

3. What were the results of the study/case or what is the status of the trial?

4. What is the importance of the case/study results or significance of the trial?

Learning Objective: Your learning objective should be a clear, concise statement of what participants should be able to do as a result of the CME activity.

Table or Image: You may add one table OR one image to your abstract (not both). Characters will not be deducted from the total character count for tables and images. 

Presentation Type: If selected, you will be notified if your presentation will be Oral or Poster.

Disclosures: All authors and presenters must disclose any conflicts of interest and acknowledge any support from commercial interests for studies relating to the abstract prior to participation in the congress. All authors and co-authors must agree with the abstract content to be considered for presentation. Identify investigational products or off-label uses of products regulated by the US FDA at first mention and where appropriate in the content, using generic names as opposed to trade names.

CONFLICT OF INTEREST POLICY As required by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, all educational planners, presenters, instructors, moderators, authors, reviewers and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with an ineligible company (the ACCME defines an “ineligible company” as any entity producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients) that have occurred within the past 24 months. The ACCME considers financial relationships to create conflicts of interest when individuals have both a financial relationship with an ineligible company and the opportunity to affect the content of CME about the products or services of that ineligible company. All identified conflicts of interest must be resolved, and the educational content vetted for fair balance, scientific objectivity and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off label; experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. ACCME does not consider providers of clinical service directly to patients to be ineligible companies.


  • No Learning Objective identified
  • Incomplete disclosure information
  • Too little data
  • Methods of study not indicated
  • Insignificant study/case
  • Abstract did not conform to guidelines
  • Author or Institution mentioned in body or title
  • Conclusion is questionable in relationship to data presented
  • Authors are employees of pharmaceutical, biotech or medical technology companies
  • Clinical number not included (for "Trials in Progress" submissions).
  • Significant data provided for "Trials in Progress" submissions.
    • Significant data should not be submitted under “Trials in Progress”, but rather be submitted for the other meeting categories providing results or endpoints.


Each abstract submitter will receive an acknowledgment of receipt of the abstract after completing a submission. If the abstract is selected for inclusion in the 5th World Congress of Cutaneous Lymphomas, the presenting author listed will receive an invitation to participate in the Congress from the Scientific Committee by late-December 2023. If the abstract is not selected, the submitting author will receive a communication regarding its decision by late-December 2023. If a first author/presenter chooses to withdraw his or her abstract for any reason, a request must be submitted by January 15, 2024. Any abstract withdrawal requests received after this date will be considered on a case-by-case basis and cannot be assured removal from the meeting materials.



Cutaneous Lymphoma Foundation Young Investigator Award (CLF YIA)  

This year's Congress will award a CLF YIA to the highest ranking abstract from Young Investigators (within 10 years from the terminal doctoral degree or fellowship training).

To be considered for the award, please submit a letter of verification from your Division or Department Head along with your Abstract, and indicate that you are applying for the Young Investigators Award.

International Society for Cutaneous Lymphomas (ISCL) Travel Scholarships

ISCL will award Travel Scholarships to select investigators from under-represented nations (including Africa, Asia and Eastern Europe), whose Abstract has been accepted. Projects that further the aims of the ISCL will be given priority consideration. 

ISCL is a non-profit worldwide association with the aims of:

  • Increasing knowledge of lymphoproliferative and related disorders of the skin.
  • Fostering collaboration among clinicians, scientists and regional or national groups by being sponsor of an international registry of cutaneous lymphomas.
  • Promoting dissemination of scientific information by organizing meetings.
  • Favoring consensus about diagnosis, management and treatment of cutaneous lymphoma.

Who Should Apply:

  • Investigators who practice or conduct research in an under-represented nations (including Africa, Asia and Eastern Europe)
    • Only those who have submitted an abstract to the 5th World Congress of Cutaneous Lymphomas and have been accepted for Oral or Poster Presentation, should apply 
      • A link to the Travel Scholarship Application will be provided upon Abstract acceptance notification.

Award Details:

  • $1,000 USD check awarded at the Congress (or wire transfer), to help with travel costs 
  • Certificate suitable for framing

Please Note: Awardees will be required to present their work in person at the 5th World Congress of Cutaneous Lymphomas, and attend the award ceremony.